Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'

(Reuters) - A top U.S. health official said Gilead Sciences Inc's experimental antiviral drug remdesivir is likely to become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped certain patients recover more quickly from the illness caused by the coronavirus.Preliminary results from a U.S. government trial show that patients given remdesivir had a 31% faster recovery time than those who received a placebo, results hailed by Dr. Anthony..